Many peptides with broad-spectrum antimicrobial activity, typically known as antimicrobial peptides (AMPs), have been isolated from a wide panel of organisms, including mammals, amphibians, molluscs, tunicates, and arthropods (Bachère et al. 2000 , Yasin et al. 2000 , van der Strate et al. 2001 , Zasloff 2002 , Bulet et al. 2004 , Chinchar et al. 2004 , Park & Hahm 2005 .
Most of them are cationic, amphipathic molecules that contain 15 to 40 amino acid residues, which can be loosely grouped into three major groups: α-helical peptides (e.g., magainins)
, cyclic and open-ended cyclic peptides with pairs of cysteine residues (e.g., defensins), and peptides with an over-representation of some amino acids (e.g., proline rich) (Yasin et al. 2000 , Zasloff 2002 , Bulet et al. 2004 .
Although the antibacterial and antifungal activities of AMPs have been the main focus of the studies to date, some of these molecules have also been shown to be effective against viral pathogens (Yasin et al. 2000 , van der Strate et al. 2001 , Oevermann et al. 2003 , Matanic & Castilla 2004 , Sun et al. 2005 . For instance, lactoferrin, a glycoprotein present in the milk, inhibited the human immunodeficiency virus (HIV-1), herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), human cytomegalovirus, respiratory syncytial virus, hepatitis B and C virus, adenovirus, and rotavirus (van der Strate et al. 2001 , Orsi 2004 in vitro, highlighting the importance of naturally occurring proteic molecules as antiviral agents.
This report describes the evaluation of the antiviral activity of nine antimicrobial peptides with different structures against HSV-1, human adenovirus respiratory strain (AdV-5), and rotavirus SA11 (RV-SA11), viruses that represent a challenge to the public health system due to their limiting symptomatic treatment.
MATERIALS AND METHODS
Antimicrobial peptides -The peptides used in this study are described in Table I . PW-2 and Gomesin were kindly donated by Dr Arnaldo Silva Junior (Unicamp, Campinas, SP) and by Dr Sirley Daffre (ICB-USP, SP, Brazil), respectively. The further evaluated peptides were extracted from the respective sources described in Table  I . Stock solutions were prepared in sterile MilliQ® water at 1 µM and stored at -20°C until use.
Cell culture and viruses -Vero (ATTC CCL-81), HEp-2 (ATCC CCL-23), and MA104 cells (ATTC CRL-2378.1) were grown and maintained in minimum essential medium (MEM, Sigma) supplemented with 10% fetal bovine serum (FBS, Gibco BRL) and 1% of antibiotics PSA (100 IU/ml penicillin G, 100 µg/ml streptomycin and 0.025 mg/ml amphotericin B; Gibco BRL) at 37ºC in a humidified 5% CO 2 atmosphere. HSV-1, KOS strain (Laboratory of Pharmacognosy, Faculty of Pharmacy, University of Rennes, France), AdV-5, and RV-SA11 (both from ICB-USP, SP, Brazil) were propagated and titrated in Vero, HEp-2, and MA104 cells, respectively.
Cytotoxicity evaluation -The cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method (Mossmann 1983 , Sieuwerts et al. 1995 , with minor modifications. Vero, HEp-2, and MA104 cells were grown in 96-well plates for 24 h at 37ºC in a humidified 5% CO 2 atmosphere. Following incubation, media was replaced with fresh MEM containing two-fold serial dilutions of the pep-tides. After 72, 96, and 120 h of incubation, respectively, for MA104, Vero, and HEp-2 cells at the same conditions mentioned above, the cytotoxicity was assessed and expressed as CC 50 (concentration that reduced the absorbance of treated cells by 50% when compared to control -untreated cells). All assays were performed in triplicate.
Antiviral assays -The antiviral assays were based upon cell viability also using the MTT method as reported by Takeuchi et al. (1991) in their studies with HSV. The technical details are described below, depending on the used strategy. For the simultaneous assay, Vero, HEp-2, and MA104 cells were grown in 96-well plates for 24 h at 37ºC in a humidified 5% CO 2 atmosphere. Following incubation, media was replaced with fresh MEM containing two-fold serial dilutions of non-cytotoxic concentrations (below CC 50 values) of the peptides and each one of the evaluated viruses (MOI = 0.5). Plates were incubated for different periods of time according to each virus: 72 h for RV-SA11, 96 h for HSV-1, and 120 h for AdV-5 at the same conditions mentioned above. The percentages of protection were calculated as [(A-B)/(C-B) × 100], where A, B, and C indicate the absorbance of the peptides, virus and control cells, respectively. The calculated EC 50 value was defined as the concentration that reduced the absorbance of infected cells to 50% when compared to infected cells and control cells. To determine whether the compounds inhibited viruses replication by affecting their adsorption or penetration on the host cells another strategy was adopted, the pretreatment assay (Bettega et al. 2004 ). Vero, HEp-2, and MA104 cells were grown as described above and following incubation, media was replaced with fresh MEM containing two-fold serial dilutions of non-cytotoxic concentrations of the peptides. Plates were incubated for 3 h prior to virus infection and further incubation periods. The percentages of protection as well as the EC 50 values were calculated as described above. All assays were performed in triplicate.
RESULTS AND DISCUSSION
All evaluated peptides were cytotoxic, in different degrees, for at least one of the cell lines after the respective period of incubation, which were equivalent to the length of time the monolayers would be exposed to the peptides during the antiviral assays (Table II) . The compounds were therefore assayed for antiviral activity at concentrations below or equal to the CC 50 values. Table III , PW-2, ALF, Gomesin, and Penaeidin-3 exhibited significant activity against HSV-1 in the simultaneous treatment. Penaeidin-3 inhibited over 85% of the viral replication at 100 µM, with an EC 50 value of 1.56 ± 0.18, resulting in a selectivity index (SI = CC 50 /EC 50 ) of 64 (data not shown). Its unique mixed structure among the evaluated peptides (a linear proline-rich N-terminal fragment with a cyclic C-terminal fragment with three disulfide bonds) may have contributed to the detected activity, since another study has already described this feature (Yasin et al. 2000 , Yang et al. 2003 .
Anti-HSV-1 effects -As shown in
In the pretreatment strategy only ALF and Mytilin A inhibited viral replication notably (Table III) . Although ALF exhibited similar percentage of inhibition in both strategies, Mytilin A presented a low percentage of inhibition in the simultaneous assay (34.28 ± 7.40) and a complete inhibition of viral replication in the pretreatment. Therefore, we speculate that this peptide, with a highly compact cysteine-rich structure, may exert its antiviral activity through a competition with the viral attachment/entry sites for binding to cell surface (van der Strate et al. 2001 ).
Anti-AdV-5 effects -Even though significant percentage of inhibition were obtained with ALF (98.17 ± 4.24) and Clavanin A (94.72 ± 5.59) in the simultaneous treatment, and with Gomesin (52.25 ± 4.27) and Clavanin A (61.54 ± 13.60) in the pretreatment, the active concen- Conc: concentrations are expressed in µM; %: results are expressed as mean ± SDM of three separate experiments; Sim: simultaneous assay; Pre: pretreatment assay; HCTF: hemocyanin C-terminal factor; ALF: antilipolysaccharide factor; At: already tested by other authors (see Murakami et al. 1991 and Yasin et al. 2000 ); Nt: not tested.
trations were too close to the CC 50 values of these peptides, resulting in low selectivity indices (data not shown).
Since most AMPs exert their antiviral activity by interfering with membranes, the activity against non-enveloped viruses is of particular interest, justifying further modifications of peptide structures to increase their selectivity (Yasin et al. 2000 , Orsi 2004 ).
Anti-RV-SA11 effects -The majority of the evaluated peptides presented low percentage of inhibition (Table  III) , except by clavanin A, which inhibited 69.40% ± 13.13 and 95.46% ± 34.42 of viral replication in the simultaneous and pretreatment assays, respectively. Although a study has described the role of clavanin A glycine residues in its interaction with lipid bilayers (van Kan et al. 2001) , the RV-SA11 does not possess a lipid envelope in its structure, thus we speculate that this peptide may exert its antiviral activity through an additional mechanism that interferes in the early steps of viral infection, since a higher percentage of viral replication inhibition was detected in the pre-treatment assay.
Despite the fact that most of the evaluated peptides that presented antiviral activity in this study were only active at concentrations too close to their CC 50 values, the results obtained here are promising, and further modifications on the peptide structures may increase selectivity, allowing upcoming investigations about their mode of action.
